What Happened to NexOptic Technology Corp?

Last week, we witnessed a roller coaster ride in one of our largest holdings, NexOptic Technology (NXO). Here’s the scoop on what happened, as we explain the tactics of how big money firms short stocks. But don’t tell anyone, it’s supposed to be a secret…

3D Signatures’ TeloView™ Software Identifies and Stages Patients With Alzheimer’s Disease From a Cheek Swab

3D Signatures Inc. announces clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.

One More Month: The Public Unveiling of Blade Optics

In exactly one month, NexOptic Technology Corp., together with Spectrum Optix, are going to reveal something really special – the world’s first-ever “flattened” telescope. You don’t want to miss it.

Flattening the Telescope — NexOptic to Unveil Blade Optics™ Prototype on April 4th

NexOptic Technology Corp. and Spectrum Optix Inc. are about to announce a major breakthrough at a media event to be held at the H.R. MacMillan Space Centre in Vancouver, British Columbia.The theme of the evening is “Flattening the Telescope,” and will mark the Companies’ first step in transforming what they believe may redefine many additional optical applications by utilizing their patent-pending Blade Optics™ lens technology.

Evaluation of the NexOptic Prototype Telescope – RASC Calgary Centre

We asked past president of the Calgary Centre of the Royal Astronomical Society of Canada, Larry McNish, to take the Blade Optics prototype for a spin. Here’s what he had to say.

NexOptic is Recognized as a Top Company per the 2017 TSX Venture 50®, Ranking Second in the Technology Sector

NexOptic has been selected for inclusion in the 2017 TSX Venture 50®, a ranking of the top performers on the TSX Venture Exchange. NexOptic is ranked second overall in the technology sector. Here’s a video on why the Company outperformed.

50/50: A Perfect Pilot Study from 3D Signatures on Blood-Based Prostate Cancer

3D Signatures Inc. just told the world that the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloViewTM software platform was a perfect 50/50. Based on blinded blood samples, TeloViewTM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.

Spectrum Achieves First Light Imagery from Prototype and Announces Public Unveiling Date

NexOptic Technology Corp. and Spectrum Optix Inc. of Calgary, Canada tells the world that they have completed assembly of their proof of concept telescope prototype lens stack and successfully captured its first set of unprocessed images of the moon.

Stealing Your Cash: The Cashless Society Revolution

Here’s a look at the current state of our Cashless Society, what it means, and the companies and governments behind this revolution.

NexOptic Technology Corp: A Revolutionary Flat Lens System

In less than 60 days, we are about to witness the unveiling of a revolutionary flat lens system that threatens the very basic concepts of physics. Here is another look at one of our favourite technology plays and what to expect.

Stephen Petranek Appointed to NexOptic Board

NexOptic Technology Corp. and Spectrum Optix Inc. of Calgary, Canada, and together with NexOptic, the “Companies” are pleased to announce that Mr. Stephen Petranek has joined the Board of Directors of NexOptic Technology Corp.

New Study Shows 3D Signatures’ Telomere Analysis May Be an Effective Biomarker for Monitoring High Risk Prostate Cancer Patients

Data from a new study1 published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.’s technology platform, TeloView™, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.